NCT02724488Completed
Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies
Source: ClinicalTrials.gov · Last updated 14 Jul 2026
Brief summary (registry, in English)
Two part prospective study to: 1. investigate the feasibility of performing ultra-deep sequencing of plasma derived circulating tumor DNA (ctDNA) in individual patients with advanced solid tumors who are currently being treated with immune checkpoint inhibitors (ICIs) and 2. obtain fresh tumor biopsies and serial blood samples to investigate the clonal evolution of tumors under the selection pressure of ICIs.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 14 (actual)
- First submitted
- 19 Nov 2015
- Start date
- 1 Apr 2015
- Primary completion date
- 31 Jan 2026
- Lead sponsor
- University Health Network, Toronto
- Diseases
- Head and neck cancer, Melanoma
- NCT number
- NCT02724488
What you commit to
- Study type: Observational
- Participants enrolled: 14
- From 1 Apr 2015 to the primary completion date, 31 Jan 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any condition that could interfere with a patient's ability to provide informed consent such as dementia or severe cognitive impairment.
- Any condition that could interfere with a patient's ability to provide informed consent such as dementia or severe cognitive impairment.
Other
- Any contraindication to undergoing a venepuncture.
- PART 2:
- Any contraindication to undergoing a biopsy procedure.
- Any contraindication to undergoing a venepuncture.
Who the study is looking for
- Age \> 18 years.
- Histological or cytological proof of metastatic solid tumors.
- Currently receiving immune checkpoint inhibitors or other immunologic therapies of interest (to be determined by study principal investigators).
- Willingness and ability of patient to provide signed voluntary informed consent.
- Age \> 18 years.
- Histological or cytological proof of metastatic solid tumors.
- At least one biopsiable lesion deemed medically accessible and safe to biopsy.
- Candidate for one or more phase I or II or III clinical trials with immune checkpoint inhibitors at the time of study enrolment. Patients receiving approved immune checkpoint inhibitors or via special access are also eligible. Patients receiving other immunologic therapies of interest may be allowed (to be determined by study principal investigators).
- Fulfills local institution's laboratory parameters for tumor biopsy.
- Willingness and ability of patient to provide signed voluntary informed consent.
Criteria the registry did not label
- PART 1:
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.